HC Wainwright Analysts Increase Earnings Estimates for VYGR

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.30). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at ($0.91) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.

Separately, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.50.

Voyager Therapeutics Trading Down 4.1%

Shares of VYGR stock opened at $3.76 on Thursday. The company has a market capitalization of $224.10 million, a price-to-earnings ratio of -1.85 and a beta of 1.32. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55. The stock’s fifty day simple moving average is $3.92 and its 200-day simple moving average is $4.19.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd raised its holdings in shares of Voyager Therapeutics by 42,410.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after acquiring an additional 15,692 shares in the last quarter. Invesco Ltd. grew its stake in Voyager Therapeutics by 28.2% in the fourth quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock valued at $456,000 after purchasing an additional 25,522 shares in the last quarter. Sphera Funds Management LTD. grew its stake in Voyager Therapeutics by 70.1% in the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock valued at $1,335,000 after purchasing an additional 140,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in Voyager Therapeutics in the 4th quarter worth about $120,000. Finally, Opaleye Management Inc. acquired a new position in Voyager Therapeutics in the 4th quarter worth about $4,704,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the sale, the chief executive officer owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This trade represents a 2.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 49,783 shares of company stock valued at $188,694. 6.39% of the stock is owned by corporate insiders.

Voyager Therapeutics News Roundup

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a large $25 price target (roughly 565% above current levels), which is a clear bullish signal that can attract buyers and lift the stock. Benzinga: HC Wainwright Reiterates Buy
• Positive Sentiment: Analyst P. Trucchio raised near-term 2026 quarterly forecasts (Q1–Q4 2026 and FY2026) — e.g., FY2026 EPS was revised from ($1.18) to ($1.09) and several quarters were nudged less negative — implying a slightly improved short-term outlook that can support a rally. AmericanBankingNews: HC Wainwright Note
• Neutral Sentiment: HC Wainwright also published updated quarterly estimates for 2027 (Q1–Q4 2027) and reiterated multi-year modeling; these scheduled estimate updates add transparency but are largely model detail rather than new fundamental catalysts. AmericanBankingNews: FY2027 Estimates
• Negative Sentiment: Offsetting the near-term upgrades, HC Wainwright lowered several longer-term EPS forecasts (FY2027–FY2030 were revised more negative — e.g., FY2027 from ($1.17) to ($1.34), FY2028 from ($1.49) to ($1.60), FY2030 from ($0.83) to ($0.91)). That signals weaker long-term profitability expectations and raises risk for longer-horizon investors. AmericanBankingNews: Long-term Estimate Cuts

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.